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Summary. Twentyninechildrenwithnon-Hodgkin'slymphomas(NHL) weretreated
between 1974 and 1977 with a protocol based on those used for childhood ALL. 76%
of patients had advanced disease by Ann Arbor criteria. All tumours had Rappaport's
diffuse histology. 19 patients (65%) achieved complete remission, 14 (65%) remained
alive and disease free beyond 42 months from diagnosis. 10 patients failed to enter
complete remission, of whom all died. 7 patients relapsed; 5 died, 2 remain disease
free and off treatment at 19 and 29 months. Comparison with a historic group of 20
consecutively treated children shows improved survival (P<0-01). 18 controls died.
Histology was reviewed using the Kiel classification and staging according to
Murphy's criteria. These are compared with the methods used initially.
The improved outlook for children with NHL using intensive multiple drug
regimes and cranial prophylaxis is confirmed. In staging childhood NHL, Murphy's
criteria, which take into account the natural history of the disease, have greater
prognostic value. Histology and pattern of outcome of the disease suggest basic
differences between primary abdominal and primary mediastinal and nodal disease.
This is now being confirmed with immunological typing and will be reflected in the
development of future protocols.
In children, non-Hodgkin's lymphomas
(NHL) are highly malignant diseases
with a poor prognosis because of frequent
relapse or transformation to acute leu-
kaemia. Following work in the late 1960s
(Aur et al., 1971) the concept that child-
hood lymphomas are potentially wide-
spread from the time of diagnosis became
accepted. In accordance with this new
approach, in 1974 the Children's Solid
Tumour Group of St Bartholomew's and
the Royal Marsden Hospital designed a
protocol for treating children with NHL.
This was based on multiple chemothera-
peutic induction of remission, prophylaxis
of the central nervous system (CNS) and a
continuation of therapy with a variety of
agents to prevent the emergence of drug
resistance and aid the complete elimina-
tion of all tumour cells. Sufficient time
has now elapsed since the introduction
of this intensive treatment programme to
evaluate its impact on survival and pos-
sible cure of these children.
PATIENTS AND METHODS
A total of 34 patients Awere admitted to this
study between September 1974 and June
1977. Five patients are excluded from this
analysis, including 3 patients who were lost
to follow-up: 1 at 1 mnonth with his original
disease and 2 in continuous first complete
remissions at 18 and 30 months. The other 2
patients were found (on reviewing the
histology) to have had inappropriate treat-
ment according to this protocol. The 29TREATMENT OF CHILDHOOD NHL
patients studied included 22 boys and 7 girls,
a male to female ratio of 341:1. They ranged
from 2 to 14 years of age (median 8).
Diagnosis was made on histology of tissue
biopsies. Cases were classified according to
Rappaport (1966). All showed a diffuse pat-
tern, with 26 patients having poorly differ-
entiated lymphoblastic infiltration, 1 histio-
cytic and 2 with true malignant histiocytosis.
The histology was reviewed recently and re-
classified according to Lennert's (1978)
modification of the Kiel classification. All
were then high-grade lymphomas: 26 were
lymphoblastic, with 10 morphologically sug-
gesting B type, 6 with convoluted nuclei
suggesting T type and 10 undefined. One
child had a histiocytic lymphoma and there
were 2 immunoblastic lymphomas. The rela-
tionship ofhistology to primary site is shown
in Table I.
TABLE I.-Primary site and histology of
29 NHL children according to the Kiel
classification
Primary
site
Nodes
Mediastinum
Abdomen
Nasopharynx
Bone
Eye
Skin
Disseminated
Lymphoblastic
B T Unde- Histio- Immuno-
type type fined cytic blastic
1 4
4 4
7
2 2
1
1
1 1
1
Investigations included complete history
and examination, full blood count, tests of
renal and hepatic function, lumbar puncture
with cytological examination of the cerebro-
spinal fluid and marrow aspirate and biopsy.
Radiological tests included chest X-rays,
lymphangiogram and intravenous urogram.
Ultrasound examination of the abdomen was
performed whenever possible. Staging lapar-
otomy was not routine, but most children
with intra-abdominal disease underwent sur-
gery, often before referral. Cell-marker studies
were not performed on any of the patients.
Staging at the time ofdiagnosis was according
to the Ann Arbor criteria, and the sites and
stage at presentation are shown in Table II.
Ofthe 29 patients, 19 had Stage IV disease at
presentation. In 13 ofthese there was marrow
involvement, but pleura, CNS and skin were
also sites ofspread. Localized disease occurred
TABLE II.-Site and stage (Ann Arbor
classification) at presentation
Stage
Site Number %
Nodes 5 17
Mediastinum 8 27-5
Abdomen 7 24
Nasopharynx 4 14
Bone 1 3-5
Eye 1 3-5
Skin 1 3-5
Disseminated 2 7
29
t N
I II III IV
1 - - 4
- - 1 7
- 4 1 2
1 1 1 1
_ _ - 1
_ _ - 1
_ _ - 1
_ _ - 2
2 5 3 19
in only 2 patients: 1 with cervical lymph-
adenopathy and 1 with a tonsillar primary.
Recently the same patients have been re-
staged using the criteria suggested by
Murphy and Hustu at St Jude Hospital,
which are shown in Table III (Murphy, 1980).
The comparison of the 2 systems is shown in
Table IV.
TABLE III.-Classification ofNon-Hodgkin
Lymphoma by Murphy (St Jude)
Stage
I Single tumour (extranodal) or single ana-
tomic area (nodal), with the exclusion
of mediastinum or abdomen.
II Single tumour (extranodal) with regional-
node involvement.
Two or more nodal areas on the same side
ofthe diaphragm.
Two single (extranodal) tumours with or
without regional node involvement on
the same side ofthe diaphragm.
Primary gastrointestinal-tract tumour,
usually in the ileocaecal area, with or
without involvement ofassociated mesen-
teric nodes only.
III Two single tumours (extranodal) on opposite
sides of the diaphragm.
Two or more nodal areas above and below
the diaphragm.
All primary intrathoracie tumours (medias-
tinal, pleural, thymic).
All extensive primary intra-abdominal
disease.
IV Any of the above with initial CNS and/or
marrow involvement.
The treatment scheme is shown in Fig. 1,
and is very similar to regimens used for acute
leukaemia. It depended on both the stage and
histology at diagnosis. Patients with Stage I
disease, unless it was affecting the medi-
astinum, were to receive radiotherapy only.
Patients with mediastinal or more wide-
spread disease were to receive chemotherapy.
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TABLE IV. Comparis
St Jude and Ann.
Stage
I
II
III
IV
Ann Arbor
2
5
3
19
Early disease
Stages I and II 7
Late disease
Stages III and IV 22
on of staging by review, and all were high grade and lympho-
Arbor systems blastic, 4 were not classified further, in 8 the
morphology suggested B type and 4 suggested
St Jude T type. These children received a variety of
23 therapies for their disease. Most received both
10 radiotherapy to the site of bulk disease and
14 chemotherapy from the time of diagnosis,
but the drugs and doses varied. Treatment
24% 5 17%
wasonlygiven to the CNS ifit becameovertly
246% 54 170o involved.
760o 24 830o
If the histology was diffuse lymphoblastic,
poorly differentiated, they received a multi-
drug scheme (shown in Figs 2 and 3) in-
volving induction, cranial prophylaxis by
cranial irradiation and intrathecal (i.t.) drugs,
and maintenance. Maintenance (Fig. 3) con-
sisted of a repeating 8-week module, with 6
weeks of oral drugs and intensification with
i.v. drugs in the 7th week, followed by one
week off therapy. This continued for 3 years.
All other diffuse histological types were
treated with 6 courses of cyclophosphamide,
Adriamycin, vincristine and prednisolone
(CHOP), which were repeated 3-weekly. Two
patients received radiotherapy only, 3 re-
ceived 6 courses of CHOP and 22 were
treated with the intensive regimen.
A series of consecutive patients from the
records of St Bartholomew's Hospital was
used for comparison with the study patients.
These children were treated between May
1962 and February 1973. There were 20
patients, 16 boys and 4 girls, with ages 1-14
years (median 8). Their sites and stages of
disease at presentation are shown in Table V.
A range of histological classification systems
was used when patients were diagnosed, but
16 of the original slides were available for
RESULTS
The disease-free survival of the 2
groups of patients is compared in Fig. 4.
Of the patients treated on this protocol 11
are alive and free of disease between 43
and 75 months from diagnosis. No patients
died after 29 months. In the historical
group only 2 patients are long-term
survivors, 18 have died. This improvement
is statistically significant (P < 001).
The treatment failures have been exam-
ined. Ten children failed to enter complete
remission; of these 4 had abdominal
disease, 2 had mediastinal disease, 2 had
peripheral-node primaries, 1 presentedwith
disseminated disease and I with a naso-
pharyngeal primary. They all died between
1 and 13 months from presentation
(median 4). Seven children who entered
remission suffered relapses. The time to
first relapse ranged from 5 to 24 months
(median 8). Five children with mediastinal
disease relapsed, 2 in the marrow, 1 in the
CNS, 1 in the mediastinum and 1 in the
testes. One boy with peripheral-node
disease relapsed in the marrow, and I girl
NON HODGKIN LYMPHOMA
TREATMENT SCHEME
Stage (except mediastinum)
RADIOTHERAPY ONLY
Stage 11 -IV + mediastinal Stage
Diffuse lymphocytic
poorly differentiated
Other diffuse histology
6 courses of:
MULTIPLE DRUGS CYCLOPHOSPHAMIIDE
+ ADRIAMYCIN
CRANIAL PROPHYLAXIS PREDNISOLONE
(Figs 2 & 3)
PENSLN
600 mg,/m2
40 mg/m2
1.4 mg/mn2
40 mg x 5 days
FIe. 1. Protocol used for the treatment of children with non-Hodgkin's lymphomas.
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Cytosine 40 mg/M2 I.T.
arabinoside
Methotrexate 10 mg/M2 I.T.
Cranial irradiation 25G y
6 Mercaptopurine 50 mg/mr2 oral
daily
EllillIll]
I_ _
Cyclophosphamide 600 mg/M2 i.v.
Vincristine 1.5 mg/mr2 i.v. st+
Then maintenance
for 3 years
Prednisilone 40 mg/M2 oral daily
FIG. 2.-Induction and
Adriamycin 40 mg/m2 i.v.
(to 400 mg/m2 )
Asparaginase 6000 u/mr i.v.
Vincristine 1.5 mg/mr2 i.v.
Cytosine arabinoside 80 mg/m2 i.v.
1 2 3 4 5 6 7 8 9 10 11 12 13
TIME IN WEEKS
cranial prophylaxis used for children with diffuse lymphocytic poorly
differentiated lymphomas.
5,
Prednisolone 40 mg/mr2 oral daily
Methotrexate 20 mg/mr2 oral wkly
Cyclophosphamide 200 mg/mr2
oral wkly 5r5,
6 Mercaptopurine 50 mg/mr2 oral
daily
WEEKS 1 2 3 4 5 6 7 8 9 11 12 FOR 3 YEARS
* I I I a I I
DAYS 1 2 3 4 5 6 7
FIG. 3. Maintenance scheme used after induction and cranial prophylaxis.
with a primary histiocytic lymphoma of and off all treatment for 19 months. The
the skin had a recurrence in the skin at a girl with skinrelapse has remained disease-
different site. Five children have died but free for 29 months after radiotherapy to
1 boy with mediastinal disease who the site ofrelapse.
relapsed in his marrow has been in a The outcome according to primary site
second complete remission for 33 months, is shown in Table VI. Nineteen of the 29
----
I
----
I a I a I a I a I a I I
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1.0
Survival 0.9
expectancy 0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
10 20
FIa. 4. Disease-free survival in
TABLE V. Site and stage (Ann.
presentation ofhistorical gro
Site
I\Iediastinum + nodcs
Abdomen
Nasopharynx
Nasopharynx + abdomen
-Number I I]
9 1 1
7 4
2 1
2 _
20 2 5
patients (65%) achieved a comp
ponse and 14 (48%) remain alive
patients with nodal and me
disease, 9/13 (69%) achieved (
remissions but only 4 (30%o) reme
With abdominal disease, fewer (3
entered a complete remission, b
who did have maintained it. Thri
4 patients with nasopharyngeal
are long-term survivors. Both
TABLE VI.-Outcome according to
site
Site Pati
No(les
Nocdes +media-
stinum
Abdtomen
Nasopharynx
Bone
Eye
Skill
Disseminated
{o. Complete
ients remission
5 3
3 6
7 :X
1 1
1
1
29 19 65-5%
Stu(dy n=29
Control n-20
30 40 50 60 70 80 110 160
Time in months
clildren treated by this protocol compared wvith the hiistorical
controls. X2 = 7-53; P < 0-01.
Arbor) at with immunoblastic lymphoma are alive
up and disease-free 58 months from diagnosis.
tage The outcome of treatment according to the stage at presentation, using both
III IV the Ann Arbor and St Jude schemes of
1 6 classification, is shown in Fig. 5. There is
I nosignificant differenceinsurvivalbetween
2 - early- and late-stage disease, using the
4 9 Ann Arbor classification, but a marked
difference is apparent with the St Jude
lete res- scheme.
e. Of the The toxicity of this protocol was
diastinal significant. Anticipated problems of
complete nausea, vomiting and alopecia occurred
%in alive. in all patients receiving chemotherapy.
,/7, 42%) Marrow suppression was the limiting
ut those factor for drug administration. Patients
ee of the receiving 6 courses of CHOP tolerated the
I disease drugs well, but for the patients on the
children intensive regimen, long-term maintenance,
and in particular the administration of
primary the intensification courses, werefrequently
modified. Although the maintenance was
originally intended for 3 years, most
Alive children could not tolerate more than 2
2 years. One child died one month into treat-
ment and before remission, with a severe
2 pneumonitis of which the cause was not
3 found. Individual reactions occurred: 1
1 child suffered convulsions after the first
1 intensification course, there was 1 allergic
response to asparaginase, and 1 vincristine
14 48.200 neuropathy.
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5
8
7
4
1
1
1
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.............................................. 1................ it .. Stage + II
:J *| | . {Stage + 11
........ I s |"|^ ffiStage III + IV
. ............ ....... IUIJ... . .e Stage III + IV
10 20 30 40 50 60 70 80
Time in months
FiG. 5. I)isease-free survival in the study patients accordting to stage at presentation. The solid
line represents staging by the Ann Arbor classification and tlhe broken line staging accordling to
Murphy's St Jucle criteria.
DISCUSSION
Anumberoftreatment programmes were
established in the early 1970s treating
children with NHL with intensive multiple
drug regimens and cranial prophylaxis.
Although management is not yet standard-
ized, a marked improvement in survival is
evideint from the recently reported series.
Using a range of treatment schemes,
disease-free survival for a minimum of
2 years, and in patients of all histologies
and stages, is reported between 55 and
7300 (Murphy & Hustu, 1980; Wollner
et al., 1979; Brecher et al., 1978; Carabell
et al., 1978). The results of our own proto-
col confirm this improvement in survival.
On comparing the control and study
groups, Tables II and V show a prepon-
derance of Stage IV cases in the study
group, 66% compared with 45%o in the
historical series. This would bias the results
of treatment against the study group.
Using the Rappaport classification of
histology, nearly all children with NHL
have a diffuse picture. In the present study
there were no nodular cases, and 26/29
patients had a lymphoblastic pattern.
This relatively homogeneous picture is
unhelpful in efforts to correlate histology
with clinical patterns and outcome of
disease. None of these children had
immunological phenotyping performed on
their tumour cells, but within the limits
of histological techniques, the Lennert
modification of the Kiel classification does
provide an indication of the cell type
(Lennert, 1978). If the relationship be-
tween the primary site at presentation
and the histology is examined, an inter-
esting picture emerges (Table I). All the
mediastinal and nodal presentations were
lymphoblastic tumours of either T type
or undefined. The B-type tumours had
predominantly abdominal and naso-
pharyngeal presentations, and did not
affect the mediastinum.
The different patterns of disease are
also apparent when the treatment failures
and the relationship between the outcome
and primary site are examined. On this
protocol, patients with mediastinal and
nodal disease entered remission quite
readily, but frequently relapsed, particu-
larly in the marrow, so that only 28%
remain alive beyond 3 years. Children
with abdominal primaries had fewer com-
plete remissions, but allthosewhoachieved
a complete response have maintained it.
The patients with nasopharyngeal and
Survival
expectancy
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
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other primary sites responded well and
remained well.
The use ofthe Ann Arbor staging system
in childhood NHL was common at the
time this study began, but the marked
differences in the natural history of NHL
and Hodgkin's disease make it unsuitable.
The comparison of survival of early- and
late-stage patients in Fig. 5 demonstrates
the low prognostic value ofthe Ann Arbor
system. The alternative scheme suggested
by Murphy and used at St Jude Hospital,
in which the most significant change is
that all intrathoracic and extensive ab-
dominal disease become Stage III, appears
to be more valuable in predicting the long-
term outcome. Our results confirm those
of other series, in that patients with
strictly localized disease have a markedly
better outlook (Murphy, 1980). These
children may well benefit from a less
intensive treatment programme without
losing their good prognosis.
In conclusion, the present study con-
firms the improvement in outlook for
children with NHL. Staging is more help-
ful ifa system which takes into account the
natural history of the disease, such as
Murphy's, is used. Basic differences be-
tween those children presenting with
abdominal and those with mediastinal and
nodal disease are suggested by the his-
tology and pattern of outcome, which are
now being confirmed with the use of
immunological typing and are reflected in
the development of current protocols.
I am grateful to Dr Alfred Stansfeld and Dr Sally
Self of the Department of Histopathology at St
Bartholomew's Hospital for revie-wing the histology,
and to MIrs Jo Barton of the Medical Oncology Uniit
for typing the manuscript.
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